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Rivaroxaban, an anti-clotting medication, acts at a crucial point in the blood-clotting process and stops 
the formation of blood clots. In this study, RP-HPLC method was developed for the determination of 
rivaroxaban in tablets (Xarelto® (10 mg)). Phenomenex Luna 5 µm C18 100 Å LC Column (250 x 4.6 mm) 
was used at 40 oC. Isocratic elution was performed with ACN:Water (55:45 v/v) mixture. The flow rate 
was 1.2 mL min-1 and UV detection was at 249 nm. Internal standard (Caffeine) and rivaroxaban were 
eluted within 2.21 and 3.37 minutes, respectively. The developed method was validated according to the 
ICH guidelines and found to be linear within the range 0.005 - 40.0 µg mL-1. The method was accurate, 
precise, robust and rapid. Thus, it was applied successfully for the quality control assay of rivaroxaban 
in tablet dosage form.
Uniterms: HPLC. Rivaroxaban. Validation. System suitability. Stability-indicating. Pharmaceutical 
dosage form.
Rivaroxabana, fármaco anticoagulante, atua em um ponto crucial no processo de coagulação do sangue 
e impede a formação de coágulos sanguíneos. Neste estudo, desenvolveu-se método de RP-HPLC 
para a determinação de rivaroxabana em comprimidos (Xarelto ® (10 mg)). Utilizou-se coluna LC 
(250 x 4,6 mm) Phenomenex Luna C18 5 mm 100 Å a 40 oC. Realizou-se eluição isocrática com ACN: 
água (55:45 v/v). O fluxo foi de 1,2 mL min-1 e a detecção de UV foi a 249 nm. Padrão interno (cafeína) 
e rivaroxabana eluíram em 2,21 e 3,37 minutos, respectivamente. O método desenvolvido foi validado 
de acordo com as diretrizes do ICH e mostrou-se linear na faixa 0,005-40,0 mg mL-1. O método foi 
exato, preciso, robusto e rápido. Assim, foi aplicado com êxito para o ensaio de controle de qualidade 
da Rivaroxabana na forma de comprimidos.
Unitermos: HPLC. Rivaroxabana. Validação. Adequação do sistema. Indicador de estabilidade. Forma 
farmacêutica.
INTRODUCTION
Anticoagulants are given to prevent the blood 
from clotting or prevent to existing clots from getting 
larger. Clots can block the blood flow to the heart 
muscle or block the blood flow to the brain. These cause 
a heart attack or a stroke. Rivaroxaban (RIV), an oral 
oxazolidinone-based anticoagulant, is a potent, selective 
direct inhibitor of factor Xa that is used in the prevention 
of venous thromboembolism in adult patients after total 
hip replacement or total knee replacement surgery. RIV 
FIGURE 1 - Chemical structure of rivaroxaban.
(Figure 1) is a small molecule (molecular mass: 436 g 
mol-1) that is almost insoluble in water and exhibits high 
plasma protein binding (92–95%) in humans, with serum 
albumin being the main binding component.
The potency of factor Xa inhibition occurs primarily 
M. Çelebier, T. Reçber, E. Koçak, S. Altınöz360
as a result of RIV binding with high selectivity to the S1 
and S4 pockets of the serine endopeptidase (Duggan et 
al., 2009). Inhibition of factor Xa interrupts the intrinsic 
and extrinsic pathway of the blood coagulation cascade, 
inhibiting both thrombin formation and development of 
thrombi. RIV does not inhibit thrombin (activated Factor 
II), and has no effects on platelets have been demonstrated 
(Pezborn et al., 2007; Terry et al., 2009). The RIV was 
approved for marketing by Health Canada and European 
Commission in 2008. In the literature, there is an HPLC-
MS method for the determination of RIV in human plasma 
for pharmacokinetic studies (Rohde, 2008). However, 
there is no method reported for the quantification of RIV 
in pharmaceutical dosage forms. It is well known that 
quality control is an important task in the pharmaceutical 
industry. The term quality control refers to the sum of all 
procedures undertaken to ensure the identity and purity 
of a particular pharmaceutical (WHO, 2010). Quality 
control measurements include stability testing of the 
drug formulation, dissolution testing and analysis of 
raw materials and synthesis products. A pharmaceutical 
company usually has to measure a large number of quality 
control samples and HPLC is a unique technique for the 
analysis of wide variety of samples (Dong, 2005). In this 
study, it was aimed to develop an accurate, precise, robust, 
rapid and selective HPLC method for determination of 
RIV in tablet dosage forms. The stability of RIV was 
evaluated and also a forced degradation procedure was 
applied under stress conditions like high temperature, 
acidic-alkali conditions, and irradiation with UV light. 
The developed method was fully validated according to 
the ICH (ICH, 2005) guidelines and observed that it was 
capable of determining RIV in the presence of forced 
degradation products. Therefore, it could be concluded 
that this method could be proposed for the quality control 
process of RIV in pharmaceutical industry.
MATERIAL AND METHODS
Chemicals and reagents
RIV working standard was supplied from Refik 
Saydam Hıfzısıhha National Public Health Agency. The 
tested pharmaceutical formulations (Xarelto® 10 mg, 
(approved in Canada, 2008) were procured from Bayer 
Turkey. Acetonitrile (ACN) was analytical grade and 
purchased from Merck.
Apparatus and Chromatographic conditions
HPLC analyses were performed on a Shimadzu UFLC 
system. Separations were carried on a Phenomenex Luna 
5 µm C18 100 Å LC Column (250 x 4.6 mm). The 
column temperature was set at 40 oC and the flow rate was 
1.2 mL min-1 while using isocratic elution with ACN:Water 
(55:45 v/v) mixture. Injection volume was 5 μL and UV 
detection was performed at 249 nm. Peak identity was 
confirmed by retention time comparison.
Preparation of standard solution
The standard stock solution of RIV (1000 µg mL-1) 
was prepared in ACN:Water (80:20 v/v) mixture. The 
working standard solutions (5.0, 10.0, 20.0, 25.0, 30.0, 
35.0 and 40 µg mL-1) were prepared by diluting the stock 
solution in the mobile phase solution. The stock solution 
was kept at +4 oC where it is stable at least one month. 
Standard solutions were daily prepared by diluting the 
stock solution with mobile phase solution.
Preparation of sample solution 
Ten tablets were weighed to get the average weight 
and grounded. An amount of powder equivalent to 10 mg 
of RIV was transferred to a 100 mL volumetric flask and 
added 70 mL of diluent (ACN:Water (80:20 v/v)) and 
sonicated for 30 min. The volume was made up with 
solvent to obtain a solution containing 100 μg mL-1 RIV. 
An aliquot was then removed and centrifuged at 5000 rpm 
for 10 min. The solution was filtered using 0.45 μm 
membrane filter paper and diluted with mobile phase to 
20 μg mL-1 before injected to the HPLC system.
Preparation of analytical placebo solution
Common inactive ingredients such microcrystalline 
ce l l u lo se  (10%,  500  mg) ,  anhydrous  d ibas i c 
calciumphosphate (83%, 4150 mg), croscarmellose 
sodium (5%, 250 mg), colloidal silicon dioxide (%1, 
50 mg), and magnesium stearate (%1, 50 mg) were 
weighed according to the ratios in a common tablet 
formulation to achieve 5 g of bulk. Then, approximately 
1 g of this bulk was used to prepare the analytical placebo 
solutions by applying the same procedure on preparation of 
tablet solutions. Synthetic tablet solutions were prepared 
by adding known amounts of RIV standard solutions to 
the analytical placebo solutions.
Forced Degradation 
High Temperature
100 µL of RIV standard stock solution was diluted 
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to 1000 µL by adding water. The concentration of RIV 
was 100 µg mL-1 in the final solution. Then the solution 
was transferred to a centrifuge tube and kept in a water 
bath for 2 h at 80 °C. The solution was cooled to room 
temperature (25 ± 5 °C), and then it was diluted with 
mobile phase to 20 µg mL-1 and injected into the HPLC 
system.
Acid and alkali hydrolysis
100 µL of RIV standard stock solution was diluted 
to 1000 µL by adding 0.1 N hydrochloric acid, or 0.1 N 
sodium hydroxide. The concentration of RIV was 
100 µg mL-1 in the final solution. Then the solution was 
transferred to a centrifuge tube and kept in a water bath 
for 2 h at 40 oC. These solutions were cooled at room 
temperature (25 ± 5 °C), after they were neutralized 
with suitable amount of hydrochloric acid or sodium 
hydroxide. The solutions were diluted with mobile phase 
to 20 µg mL-1 and injected into the HPLC system.
Irradiation with ultraviolet light
100 µL of RIV standard stock solution was diluted 
to 1000 µL by adding water. The concentration of RIV 
was 100 µg mL-1 in the final solution. The solution was 
exposed to UV light (254 nm) combined with tungsten 
lamp for 24 hours at room temperature. The solution was 
then diluted with mobile phase to 20 µg mL-1 and injected 
into the HPLC system.
Stability studies
The purpose of stability testing is to provide evidence 
on how the quality of drug product varies with time under 
the influence of a variety of environmental factors such 
as temperature, humidity, and light. The standard stock 
solution of RIV (1000 µg mL-1) prepared in ACN:Water 
(80:20 v/v) was divided into two volumetric flasks (5 mL). 
These volumetric flasks were prevented from daylight 
and the first one was kept at room temperature, while the 
second one was kept at 4 oC inside the refrigerator. The 
stability of RIV at room temperature was evaluated in 
short term period (24 h), while the stability at 4 oC was 
evaluated for 72 h (short-term) and 1 month (long-term). 
The solutions were then diluted with mobile phase to 
20 µg mL-1 and injected into the HPLC system.
RESULTS AND DISCUSSION
For developing and validating an HPLC method, 
the most common approach is to optimize the mobile 
phase composition after an appropriate column has been 
selected (Synder et al., 1997). RIV is a non-hygroscopic 
powder only slightly soluble in organic solvents and 
it is practically insoluble in water and aqueous media. 
According to our observation, RIV was slightly dissolved 
in methanol (MeOH) on the preparation of standard stock 
solutions process. Therefore, the solubility of RIV was 
tested simply in various organic solvents in the initial 
experiments and it was concluded that RIV was clearly 
soluble in acetonitrile (ACN). Thus, it was decided to use 
the mixture of ACN and water in different proportion on 
the separation of RIV through C18 column. Since caffeine 
could be eluted with ACN:water mixture without using any 
buffer and it is an easy to find chemical for quality control 
laboratories, it was used as the internal standard (IS) for 
the experiments. A well-defined peak for caffeine was 
observed at 2.21 min. under the experimental conditions. 
Even though the column temperature is an important 
parameter on separation of organic compounds by HPLC, 
the effect of the solvent strength is usually stronger than 
the effect of temperature on solute retention (Cuiru et al., 
2005). It was seen that changing the column temperature 
between 30–40 oC, changed the retention time of RIV not 
more than 5% and did not effect the retention time of IS 
noticeably. According to the results, it was obvious that 
RIV could be easily separated and analyzed less than 4 
minutes in various conditions given in Table I. However, 
it was observed that better peaks shapes were obtained 
by increasing the temperature of the column. Since, the 
backpressure of the column was tolerable, the flow rate 
was kept at 1.2 mL min-1 to improve the efficiency besides 
decreasing the retention time. In conclusion, it was decided 
to use ACN-Water ratio as 55:45 (v/v) at 40 oC to perform 
the analyses. The UV Spectrum of the RIV in mobile phase 
shows clearly that 249 nm is better to use in to observe 
the maximum absorbance while it is being prevented 
from interference coming from matrix components. The 
chromatograms of standard, tablet, analytical placebo 
solutions and RIV solution degraded at high temperature 
taken under optimum conditions are given in Figure 2.
System Suitability
The system suitability test was applied to the 
chromatograms taken under optimum conditions to check 
various parameters such as column efficiency (plates), 
peak tailing, capacity factor, and resolution. Suitable 
resolution (>1.5) and column efficiency (>2000) were 
achieved for the proposed method while the total analysis 
time was shorter than 4 minutes. The system suitability 
results are given in Table II. The RSD of six consecutive 
injections was found to be 0.25%, and 0.28% for IS and 
RIV, respectively. All these results assure the adequacy of 
M. Çelebier, T. Reçber, E. Koçak, S. Altınöz362
TABLE I - Retention time of IS and RIV on various conditions of mobile phase composition and chromatographic column temperature
Conditiona
Mobile Phase Composition Temperature Flow Rate Retention Time
ACN H2O
oC mL min-1 IS RIV
1 60 40 40 1.20 2.167 2.976
2 55 45 40 1.20 2.216 3.371
3 50 50 40 1.20 2.268 3.965
4 60 40 35 1.20 2.166 3.004
5 55 45 35 1.20 2.214 3.430
6 50 50 35 1.20 2.270 4.061
7 60 40 30 1.20 2.168 3.061
8 55 45 30 1.20 2.208 3.491
9 50 50 30 1.20 2.271 4.147
aCondition 2 is selected to perform the analysis
FIGURE 2 - Representative chromatograms obtained under the optimum chromatographic conditions for RIV standard, RIV tablet, 
analytical placebo solutions and RIV solution degraded at high temperature.
the proposed HPLC method for routine analysis of RIV.
Method validation
The proposed method was validated as to selective, 
linearity range, sensitivity, precision, accuracy, robustness 
and ruggedness according to the ICH guideline (ICH, 
2005).
Forced degradation and stability studies
The stability of RIV in aqueous solutions was 
investigated for two different purposes. The first one was 
to identify the stability of RIV and to show the selective 
analysis of RIV in various extreme stress conditions. 
The second one was to clarify the stability of standard 
solutions for short and long term at room temperature and 
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TABLE II - System suitability parameters for the proposed 
method
RIV IS
Retention Time (min) 3.37 2.21
Capacity Factor (k’) 1.32 0.52
Efficiency (N) 7997 6369
Peak Symmetry 1.18 1.39
Resolution 8.9
inside refrigerator. The ICH guideline entitled stability 
testing of drug substances and products requires the stress 
testing to be carried out to elucidate the inherent stability 
characteristics of the active substance, and provide a 
rapid identification of differences that might result from 
changes in the manufacturing processes or source sample 
(ICH, 2005). The aim is to quantify the standard drug 
alone and resolve its degradation products (Bakshi et al., 
2002). As described in the experimental section, different 
stress conditions were applied: high temperature, acid-
base hydrolysis and irradiation with UV light. Under all 
these conditions the degradation products were observed 
at 1.35 min (Figure 2). The method was able to separate 
completely the degradation products from the intact RIV. 
As shown in Figure 2, it is confirmed the selectivity of 
the proposed method with the presence of the degradation 
products. Stability studies of RIV at room temperature for 
24 h, 4 oC refrigeration temperature for 72 h (short-term) 
and 1 month (long-term) were also investigated. Forced 
degradation and stability studies show that RIV was stable 
at root temperature for 24 h and stable at 4 oC refrigeration 
temperature at least for 1 month, but not stable in acidic 
and alkaline medias and also not stable in high temperature 
and under the UV light. The forced degradation and 
stability results are given in Table III.
Selectivity
Selectivity of a method refers to the extent to 
which it can determine particular analyte(s) in a complex 
mixture without interference from other components in 
the mixture. Selectivity of the method was evaluated by 
preparing the analytical placebo sample, standard solution 
and sample of commercial pharmaceutical formulation. 
A solution of analytical placebo (containing all the tablet 
excipients except RIV) was prepared as given in the sample 
preparation procedure and injected into the HPLC system. 
The placebo chromatograms did not show any other peaks, 
thus, it was confirmed the selectivity of the method. The 
peak purities confirmed that the peaks on the standard 
solutions, tablet solutions and forced degradation solution 
are not interfered coming from matrix components. The 
retention times of peaks and peak areas were identical 
for the standard solutions and the tablet solutions and the 
method was capable of separating RIV and IS from forced 
degradation products. The chromatograms of standard, 
tablet, placebo and forcedly degraded RIV solutions were 
given in Figure 2.
Linearity
The linearity of an analytical procedure is its ability 
(within a given range) to obtain test results, which are 
directly proportional to the concentration (amount) of 
analyte in the sample. Calibration curve was constructed 
for RIV standards by plotting the concentrations versus 
peak area ratios. The graph proved that the method was 
linear up to 40 µg mL-1. Eight different standard solutions 
within the linear range containing 5.0, 10.0, 20.0, 25.0, 
30.0, 35.0 and 40 µg mL-1 of RIV and 40 µg mL-1 of IS 
were prepared and injected into the HPLC system. The 
linearity was evaluated by linear regression analysis 
and the regression equations were calculated from the 
calibration graphs, along with the standard deviations of 
the slope (Sb) and intercept (Sa) of the calibration curve 
(Table IV).
Sensitivity
Limit of detection (LOD) and quantification (LOQ) 
TABLE III - Recuperation (%) of RIVa after the exposition on various conditions of temperature, pH and UV light
Condition Room Temperature Refrigerator Temperature
Acidic 
Solution Basic Solution
High 
temperature UV light
Temperature 25 oC 4 oC 40 oC 40 oC 80 oC 25 oC
Time 24 h 72 h 1 month 2 h 2 h 2 h 24 h
Stability (%)b 100.5 ± 0.1 100.1 ± 0.2 99.0 ± 0.2 83.2 ± 0.1 83.0 ± 0.2 77.7 ± 0.2 35.1 ± 0.2
aRIV solutions were prepared as described in experimental section and prevented from daylight. bStability results are given as 
Recovery (%) ± RSD while n=6 and the added concentration of RIV is 20 µg mL-1
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are estimated from the signal-to-noise ratio. The detection 
limit is defined as the lowest concentration level resulting 
in a peak height of three times the baseline noise. The 
quantitation limit is defined as the lowest concentration 
level that provided a peak height with a signal-to-noise 
ratio higher than 10, with precision (RSD%) and accuracy 
(Bias%) within ±10%. LOD and LOQ values of HPLC 
method were determined to be 0.001 and 0.005 µg mL-1, 
respectively (Table IV).
Precision and Accuracy
Accuracy of the assay method was determined for 
both intra-day and inter-day variations using the six times 
analysis of the quality control samples. Three different 
concentrations of standard RIV solutions (within the 
linear range) were analyzed on six consecutive days 
(inter-day precision) and six times within the same day 
(intra-day precision). The obtained values for relative 
standard deviation (RSD) and Bias of intra- and inter-day 
studies indicated that the precision and accuracy of the 
method were satisfactory. The results are summarized 
in Table V.
Recovery
In order to know whether the excipients in the 
pharmaceutical formulations interfere with the analysis, 
the recovery tests were performed by standard addition 
technique. Three concentration levels were selected and 
known amounts of RIV standard solutions were added 
into the tablet solutions. The final concentrations were 
within the linear range. These solutions were prepared 
three times and analyzed through the developed method. 
Comparison of the intercepts of calibration curve 
(0.0952 ± 0.007 (mean ± SE)) with standard additions 
technique (0.0936 ± 0.0201 (mean ± SE)) indicates that 
they were identical and there was no interference coming 
from matrix components. The other perspective on 
recovery studies was to analyze synthetic tablet solutions 
by the proposed method. Synthetic tablet solutions were 
prepared six times and analyzed by the developed method 
and 97.89 ± 0.68 percent of the standard RIV were 
recovered from synthetic tablet solutions.
Robustness
The robustness of an analytical procedure is a 
measure of its capacity to remain unaffected by small but 
deliberate variations in method parameters and provides 
an indication of its reliability during normal usage. The 
variations on column temperature (± 5 oC) and ratio 
of organic content in the mobile phase (± 5% on ACN 
volume) did not have any significant effect on response. 
The peak area ratios were changed relatively between 
99.8 – 102.4% within these small changes on mobile 
phase component and column temperature. The results 
were evaluated statistically, and there were no significant 
differences (p>0.05) within the results.
Reproducibility
Applying same procedures by two different 
operators showed the ruggedness of the developed method. 
The analysis results having no significant difference 
indicate that the proposed method is robust.
TABLE V - Precision and accuracy of the developed method
Added 
(mg mL-1)
Intra-day Inter-day
Founda 
(mg mL-1)
Precisionb 
RSD %
Accuracyc 
Bias %
Found 
(mg mL-1)
Precision 
RSD %
Accuracy 
Bias %
RIV 10 10.26 ± 0.13 2.15 2.56 9.80 ± 0.08 1.33 -1.98
20 20.15 ± 0.16 1.34 0.74 20.23 ± 0.35 3.01 1.16
35 35.15 ± 0.30 1.49 0.41 35.06 ± 0.11 0.52 0.16
aFound: mean ± standard error (n=6); bRSD: Relative standard deviation; Bias: [(Found - Added)/Added] x 100
TABLE IV - Linearity of RIV analyses by the developed method
Method Range (µg mL-1) Calibration Curvea Sa Sb R2 LOQ LOD
HPLC 5.0 -40.0 y = 0.0952x – 0.0330 0.0007 0.0183 0.9997 0.005 0.001
a Based on six calibration curves where y: peak area ratio and x: concentration of RIV as µg mL-1; Sa: Standard error of intercept 
and Sb: Standard error of slope; R2: Regression coefficient; LOQ: Limit of quantitation; LOD: Limit of detection
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Application of the developed method
The validated method was applied for  the 
determination of RIV in commercially available Xarelto® 
(10 mg) tablets. Figure 2 illustrates a typical type of HPLC 
chromatogram of tablet solution of RIV at a retention 
time 3.37 min with no interference of excipients present 
in tablets. The tablet analysis results were given in Table 
VI. The results of the assay (n=6) yielded 100.94% 
(RSD = 1.17 and SE = 0.53) of the labeled claim. These 
results indicate that the method is selective for the analysis 
RIV without interference of the excipients. The low RSD 
value with proper accuracy indicates the suitability of this 
method for the routine analysis of RIV.
CONCLUSION
In the present study, an attempt was made to 
develop a simple, accurate, selective and sensitive 
RP-HPLC method of RIV in pharmaceutical analysis. 
This method is the only reported method up to date for 
the determination of RIV in pharmaceutical dosage 
forms. The method was validated for selectivity, 
accuracy, linearity, precision (inter-day and intra-day), 
sensitivity, robustness and ruggedness in accordance 
with ICH guidelines. The results from stress testing, 
including separation of the degradation product and 
quantification of RIV after exposure to stress conditions 
show the method is stability-indicating and capable of 
determining RIV in presence of its degradation products, 
which indicates the selectivity of the method. A simple 
mobile phase without preparation of any buffer solution 
or adding ion-pairing agents and a short run time are 
advantageous and make this method suitable for routine 
analysis of large number of samples per day.
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